ライフサイエンスコーパス: povidone-iodine

1 AP) and a repeated submucosal application of Povidone-iodine.

2 P), and a repeated submucosal application of povidone-iodine.

3 er 12 months (P = 0.045 and P = 0.002) using povidone-iodine.

4 ght benefit seemed to derive from the use of povidone-iodine.

5 is more protective against infection than is povidone-iodine.

6 of iodine rather than isopropyl alcohol plus povidone-iodine.

7 ant difference between the effect of topical povidone-iodine 1.25% and topical antibiotics commonly a

8 To compare povidone-iodine 1.25% ophthalmic solution with topical a

9 Povidone-iodine 1.25%, which is widely available and ine

10 ation rates were determined to be 2.93% with povidone-iodine, 2.58% with tincture of iodine, 2.50% wi

11 preparation for intravitreal injection using povidone-iodine 5% alone in the absence of postinjection

12 The preoperative use of povidone-iodine 5% and the postoperative use of impregna

13 paration consisted of topical anesthetic and povidone-iodine 5% without the use of preinjection or po

14 The preoperative use of povidone-iodine 5%, dilute intracameral antibiotics (via

15 to include use of a sterile lid speculum and povidone iodine (5%).

16 Skin antisepsis was performed with 10% povidone-iodine, 70% isopropyl alcohol, tincture of iodi

17 28773 injections (3120 eyes) performed with povidone-iodine, 9 cases of endophthalmitis occurred: 6

18 cohol was significantly more protective than povidone-iodine against both superficial incisional infe

19 sinfection with polyvinylpyrrolidone (PVP or povidone)-iodine-alcohol and the correlation with postop

20 Patients were 32.7% and 33.9% female in the povidone iodine and chlorhexidine gluconate groups, resp

21 .5 to 0.7 days) and in India was 12 days for povidone-iodine and 17 days for ciprofloxacin (95% CI, -

22 sumed cure in the Philippines was 7 days for povidone-iodine and 7 days for neomycin-polymyxin B-gram

23 opriate wound construction, a combination of povidone-iodine and antibiotics provide a reasonable app

24 Continued use of povidone-iodine and consideration to eliminate topical a

25 ement: The subxyphoid area was cleansed with povidone-iodine and draped.

26 very surgical facility, including periocular povidone-iodine and intracameral moxifloxacin.

27 ng intravitreous injections with and without povidone-iodine and rates with and without topical antib

28 doxycycline, 100 mg for 2 weeks; 3) topical povidone-iodine and systemic doxycycline, 100 mg for 2 w

29 reparation wipes (alcohol, chlorhexidine and povidone iodine) and found that during wiping they reduc

30 Objective: To assess whether povidone-iodine application at the end of adjustable sut

31 echanical debridement measures with adjuvant Povidone-iodine application with and without systemic an

32 echanical debridement measures with adjuvant povidone-iodine application with and without systemic an

33 s for repair of cardiac defects and received povidone-iodine as a preoperative antiseptic.

34 eive a nasal antiseptic solution, containing povidone-iodine as the main ingredient, (n = 25) or a co

35 This study was not able to demonstrate that povidone-iodine at the end of adjustable suture strabism

36 1 (with povidone-iodine) or group 2 (without povidone-iodine) at the end of surgery.

37 rom 2 participants were administered without povidone-iodine; both participants developed endophthalm

38 nd listed on the ClinicalTrials.gov website: povidone-iodine, chlorhexidine, hydrogen peroxide, cyclo

39 was to test the hypothesis that preoperative povidone-iodine contributes to postoperative thyroid dep

40 ine washcloths and oral rinse and intranasal povidone-iodine decreased the SSI rate by more than 50%

41 Povidone-iodine demonstrated greater ocular surface disc

42 Interventions: One drop of 5% povidone-iodine directly over the sliding noose of the a

43 Over a 5-year period, for povidone-iodine drops before performing intravitreal inj

44 xidine-alcohol is superior to cleansing with povidone-iodine for preventing surgical-site infection a

45 de, 0.12% chlorhexidine digluconate, or 7.5% povidone-iodine for subgingival irrigation during SRP.

46 f patients was 65.0 years (39.0-79.0) in the povidone iodine group and 65.0 years (41.0-78.0) in the

47 were identified in 80 patients (5.1%) in the povidone iodine group vs 97 (5.5%) in the chlorhexidine

48 the chlorhexidine-alcohol group than in the povidone-iodine group (9.5% vs. 16.1%; P=0.004; relative

49 eumonia occurred in 24 patients (31%) in the povidone-iodine group and 20 (28%) in the placebo group

50 acheobronchitis: eight patients (10%) in the povidone-iodine group and five patients (7%) in the plac

51 ss syndrome occurred in five patients in the povidone-iodine group but not in the placebo group (p =

52 The povidone-iodine group had the highest clinical improveme

53 e chlorhexidine-alcohol group and 440 in the povidone-iodine group) qualified for the intention-to-tr

54 tion-to-treat population) was 150 (78 in the povidone-iodine group, 72 in the placebo group).

55 re divided into two groups: Group 1 received povidone-iodine; group 2 received chlorhexidine as a top

56 ares favorably with previous series in which povidone-iodine has been used.

57 Povidone iodine in alcohol as preoperative skin antiseps

58 d are non-irritating, unlike preparations of povidone iodine in our assays.

59 e regarding the risk of endophthalmitis when povidone-iodine is not used before intravitreous injecti

60 only a small number of eyes did not receive povidone-iodine just prior to an intravitreous injection

61 onic debridement, STC and GPAP with adjuvant Povidone-iodine led to significant clinical improvements

62 nic debridement, STC, and GPAP with adjuvant povidone-iodine led to significant clinical improvements

63 uction was observed after the application of povidone-iodine (log(10) 3.68 +/- 0.69 at 5 min; log(10)

64 Likewise, multiuse povidone-iodine may allow for large relative cost reduct

65 dition of topical 0.1% amphotericin B and 5% povidone iodine might be optional effective regimens for

66 assigned to receive oropharyngeal care with povidone-iodine (n = 91) or placebo (n = 88) six times d

67 tion shields for pulmonary artery catheters; povidone-iodine ointment applied to insertion sites of h

68 e randomly assigned each month to either use povidone iodine or chlorhexidine gluconate, each formula

69 The choice of antiseptic agent, povidone iodine or chlorhexidine gluconate, remains deba

70 acterial keratitis to topical treatment with povidone-iodine or antibiotics (neomycin-polymyxin B-gra

71 ing assigned participants into group 1 (with povidone-iodine) or group 2 (without povidone-iodine) at

72 yes using topical 0.1% amphotericin B and 5% povidone iodine (P = .008 and .021, respectively).

73 icidal activity of various concentrations of povidone iodine (PI) solution in an agar plate experimen

74 ageenan (Carr-NS), nitric oxide (NO-NS), and povidone iodine (PI-NS).

75 While povidone-iodine (PI) is a commonly used antiseptic solut

76 Povidone-iodine (PI) is the current gold standard for an

77 Topical povidone-iodine (PI) is widely used as an ocular surface

78 Povidone-Iodine (PI) may be diluted when used as an anti

79 y aims to investigate the effect of diluting povidone-iodine (PI) on bacterial growth from bacterial

80 nts followed a pre-IVI asepsis protocol with povidone-iodine (PI).

81 hexidine gluconate plus alcohol vs 6.5% with povidone iodine plus alcohol); maintaining normothermia

82 plants were exposed to three antimicrobials: povidone-iodine (PovI; 0.05%, 1%, and 5%), chlorhexidine

83 tication (P/D) and hyperthermic intrapleural povidone-iodine, prophylactic chest wall radiotherapy an

84 milar analyses were performed for a multiuse povidone-iodine protocol for intravitreal injections.

85 l activity of 0.12% chlorhexidine (CHX), 10% povidone iodine (PVD), Vega oral care gel (VEGA), and an

86 Chlorhexidine (CHX) and povidone-iodine (PVI) are used for skin antisepsis, mini

87 al was conducted to test the hypothesis that povidone-iodine (PVI) irrigation versus no irrigation (N

88 Povidone-iodine (PVI) is principally used as an antimicr

89 es suggested that compared with tears, after povidone-iodine (PVP-I) alone (2 studies, 409 participan

90 This review article addresses the effects of povidone-iodine (PVP-I) and its utility in the treatment

91 A pre-IVI asepsis protocol with povidone-iodine (PVP-I) was applied.

92 Preoperative application of povidone-iodine remains the standard protocol for the pr

93 n with either chlorhexidine-alcohol scrub or povidone-iodine scrub and paint.

94 orhexidine skin cleanser was substituted for povidone-iodine solution during initial aseptic preparat

95 hexidine washcloths and oral rinse and nasal povidone-iodine solution to be used the night before and

96 investigates the efficacy of nasopharyngeal povidone iodine solutions in reducing the viral load of

97 e effective for catheter insertion care than povidone-iodine solutions to prevent catheter-associated

98 Lid speculum use, povidone iodine strength (5% vs. 10%), injection locatio

99 was swept with a culture swab before use of povidone iodine; the inferior fornix of the fellow eye w

100 e is no evidence to recommend oral care with povidone-iodine to prevent ventilator-associated pneumon

101 rgery is not well defined, and the effect of povidone-iodine use on suture colonization is unknown.

102 r periods) were randomly assigned to receive povidone iodine vs 1762 patients (26 cluster periods) to

103 , SSIs were present in 4.2% of patients with povidone iodine vs 3.3% with chlorhexidine gluconate (re

104 inal surgery, SSIs were present in 6.8% with povidone iodine vs 9.9% with chlorhexidine gluconate (re

105 The unadjusted relative risk for povidone iodine vs chlorhexidine gluconate was 0.92 (95%

106 ) for presumed cure among those treated with povidone-iodine (vs antibiotics) was 1.46 in the Philipp

107 No adverse effects of povidone-iodine were observed.

108 0% isopropyl alcohol, tincture of iodine, or povidone-iodine with 70% ethyl alcohol (i.e., Persist).